Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [916]

First in-human trials of rovalpituzumab for SCLC

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

First in-human trials of rovalpituzumab for SCLC ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA )

Photon vs proton beam therapy: modality in radiotherapy for non-small cell lung...

Dr Madhusmita Behera - Emory University, Atlanta, USA

Photon vs proton beam therapy: modality in radiotherapy for non-small cell lung cancer ( Dr Madhusmita Behera - Emory University, Atlanta, USA )

Antibody drug conjugate shows early promise in small cell lung cancer

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA

Antibody drug conjugate shows early promise in small cell lung cancer ( Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York, USA )

Liquid biopsy may help guide treatment decisions for advanced solid tumours

Prof Philip Mack - University of California Davis, Davis, USA

Liquid biopsy may help guide treatment decisions for advanced solid tumours ( Prof Philip Mack - University of California Davis, Davis, USA )

Precision medicine selection with MyPathway for solid tumours

Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA

Precision medicine selection with MyPathway for solid tumours ( Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA )

Liquid biopsy may help guide treatment decisions for advanced solid tumours

Prof Philip Mack - University of California Davis, Davis, USA

Liquid biopsy may help guide treatment decisions for advanced solid tumours ( Prof Philip Mack - University of California Davis, Davis, USA )

Direct activation of STING in the tumour microenvironment leads to potent and...

Dr Thomas Dubensky - Aduro Biotech, Berkley, USA

Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity ( Dr Thomas Dubensky - Aduro Biotech, Berkley, USA )

Understanding personalised medicine - the e-learning course

Prof Gordon McVie

Understanding personalised medicine - the e-learning course ( Prof Gordon McVie )

Editor's Choice for April 2016

Prof Gordon McVie - ecancer Editor

Editor's Choice for April 2016 ( Prof Gordon McVie - ecancer Editor )

Novel technologies for understanding the repertoire of tumour infiltrating T...

Prof Sine Reker Hadrup - Technical University of Denmark, Kongens Lyngby...

Novel technologies for understanding the repertoire of tumour infiltrating T cells in cancer ( Prof Sine Reker Hadrup - Technical University of Denmark, Kongens Lyngby, Denmark )

Patient perspective on immunotherapy and the ITOC-3 conference

Peter Trayhurn - Patient advocate

Patient perspective on immunotherapy and the ITOC-3 conference ( Peter Trayhurn - Patient advocate )

Targeting tumour vasculature by DNA vaccines

Dr Andrea Facciabene - University of Pennsylvania, Philadelphia, USA

Targeting tumour vasculature by DNA vaccines ( Dr Andrea Facciabene - University of Pennsylvania, Philadelphia, USA )

More from ecancer